Gerold Bepler

14.2k total citations · 1 hit paper
238 papers, 10.4k citations indexed

About

Gerold Bepler is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Gerold Bepler has authored 238 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 114 papers in Pulmonary and Respiratory Medicine, 106 papers in Molecular Biology and 102 papers in Oncology. Recurrent topics in Gerold Bepler's work include Lung Cancer Treatments and Mutations (95 papers), Lung Cancer Research Studies (42 papers) and RNA modifications and cancer (33 papers). Gerold Bepler is often cited by papers focused on Lung Cancer Treatments and Mutations (95 papers), Lung Cancer Research Studies (42 papers) and RNA modifications and cancer (33 papers). Gerold Bepler collaborates with scholars based in United States, Germany and Spain. Gerold Bepler's co-authors include George R. Simon, Eric B. Haura, Alan Cantor, Zhong Zheng, Edward F. Patz, Anupama Sharma, Philip C. Goodman, Tawee Tanvetyanon, Ashish Gautam and Swati Sharma and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Gerold Bepler

231 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Establishment and identification of small cell lung cancer cell lines having classic and variant features

1986 788 citations Gerold Bepler et al. profile →

Peers

Countries citing papers authored by Gerold Bepler

Since Specialization

Citations

This map shows the geographic impact of Gerold Bepler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerold Bepler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerold Bepler more than expected).

Fields of papers citing papers by Gerold Bepler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerold Bepler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerold Bepler. The network helps show where Gerold Bepler may publish in the future.

Co-authorship network of co-authors of Gerold Bepler

This figure shows the co-authorship network connecting the top 25 collaborators of Gerold Bepler. A scholar is included among the top collaborators of Gerold Bepler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerold Bepler. Gerold Bepler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe 2023 ·NAR Cancer ·Joshua Heyza, (unknown), (unknown), (unknown), Christopher K. Yunker, (unknown), (unknown), Lisa Polin, (unknown), Eric Van Buren, Donovan Watza, (unknown), Wei Chen, Hirva Mamdani, Ann G. Schwartz, John J. Turchi, Gerold Bepler, Steve M. Patrick	4
2	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib 2022 ·Clinical Lung Cancer ·D. Ross Camidge, Teresa Morán, Ingel Demedts, (unknown), Kathryn F. Mileham, Julian R. Molina, Óscar Juan, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert F. Smit	19
3	The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer 2021 ·Clinical Lung Cancer ·Misako Nagasaka, Vijendra K. Singh, Yasmine Baca, Ammar Sukari, Chul Kim, Hirva Mamdani, Alexander I. Spira, Dipesh Uprety, Gerold Bepler, Edward S. Kim, Luis E. Raez, Sachin Gopalkrishna Pai, Chukwuemeka Ikpeazu, Matthew J. Oberley, Rebecca Feldman, Joanne Xiu, W. Michael Korn, Antoinette J. Wozniak, Hossein Borghaei, Stephen V. Liu	21
4	Physical activity and quality of life in African American cancer survivors: The Detroit Research on Cancer Survivors study 2020 ·Cancer ·Jennifer Beebe‐Dimmer, Julie J. Ruterbusch, Felicity W. K. Harper, (unknown), (unknown), Andrew Rundle, (unknown), Theresa A. Hastert, Kendra Schwartz, Gerold Bepler, Michael S. Simon, Julia Mantey, (unknown), (unknown), Ann G. Schwartz	36
5	The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53 2020 ·Cell Death and Disease ·Hu Chen, Mu Zhang, (unknown), (unknown), Lisa Polin, Wei Chen, Hyejeong Jang, Joshua Heyza, (unknown), Joseph A. Caruso, Shengyan Xiang, Steve M. Patrick, Paul M. Stemmer, Zhenkun Lou, Wenlong Bai, Chuangui Wang, Gerold Bepler, (unknown)	48
6	Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non–Small Cell Lung Cancer Patients 2019 ·Clinical Cancer Research ·Christine M. Lusk, Donovan Watza, Greg Dyson, Douglas B. Craig, (unknown), Angela S. Wenzlaff, Fulvio Lonardo, Aliccia Bollig‐Fischer, Gerold Bepler, Kristen S. Purrington, Shirish M. Gadgeel, Ann G. Schwartz	18
7	Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer 2018 ·Clinical Cancer Research ·Joshua Heyza, (unknown), Donovan Watza, Hao Zhang, Wei Chen, (unknown), Ann G. Schwartz, Gerold Bepler, Steve M. Patrick	24
8	Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes 2018 ·Carcinogenesis ·Donovan Watza, Christine M. Lusk, Gregory Dyson, Kristen S. Purrington, Kang Chen, Angela S. Wenzlaff, (unknown), Christine Neslund‐Dudas, Gerold Bepler, Ann G. Schwartz	4
9	SMARCA4 /BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer 2015 ·Clinical Cancer Research ·Erica H. Bell, Arup R. Chakraborty, Xiaokui Mo, Ziyan Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell, Gerold Bepler, David P. Carbone, Arnab Chakravarti	115
10	Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination 2015 ·Cancer Immunology Research ·Heather M. Gibson, Jesse Veenstra, Richard Jones, Ulka N. Vaishampayan, (unknown), Gerold Bepler, Lawrence G. Lum, Joyce Reyes, Amy Weise, Wei‐Zen Wei	11
11	β-Arrestin-1 Mediates Nicotine-Induced Metastasis through E2F1 Target Genes That Modulate Epithelial–Mesenchymal Transition 2015 ·Cancer Research ·Smitha Pillai, José G. Treviño, Bhupendra Rawal, Sandeep Singh, Michelle Kovacs, Xueli Li, Michael J. Schell, Eric B. Haura, Gerold Bepler, Srikumar Chellappan	73
12	RRM1, ERCC1 and TS1 Immunofluorescence Expression in Leiomyosarcoma: A Tissue Microarray Study with Clinical Outcome Correlation Analysis 2015 ·Pathology & Oncology Research ·(unknown), (unknown), Alberto Chiappori, Gerold Bepler, Marilyn M. Bui	0
13	Racial Diversity of Actionable Mutations in Non–Small Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·Aliccia Bollig‐Fischer, Wei Chen, Shirish M. Gadgeel, Angela S. Wenzlaff, Michele L. Coté, Ann G. Schwartz, Gerold Bepler	41
14	High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma 2009 ·Clinical Cancer Research ·Valsamo Anagnostou, Gerold Bepler, Konstantinos N. Syrigos, L.T. Tanoue, Scott Gettinger, Robert Homer, Daniel J. Boffa, Frank C. Detterbeck, David L. Rimm	29
15	Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non–Small-Cell Lung Cancer 2007 ·Journal of Clinical Oncology ·George R. Simon, Anupama Sharma, Xueli Li, Todd R. Hazelton, Frank Walsh, Charles C. Williams, Alberto Chiappori, Eric B. Haura, Tawee Tanvetyanon, Scott Antonia, Alan Cantor, Gerold Bepler	147
16	The Guinea Pig Syndrome: Improving Clinical Trial Participation among Thoracic Patients 2007 ·Journal of Thoracic Oncology ·Gwendolyn P. Quinn, Bethany A. Bell, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Charles C. Williams, Gerold Bepler	38
17	ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer 2005 ·CHEST Journal ·George R. Simon, Swati Sharma, Alan Cantor, (unknown), Gerold Bepler	225
18	Hot spots for molecular genetic alterations in lung cancer. 1999 ·PubMed ·Diana M. Pitterle, (unknown), Gerold Bepler	26
19	Human chorionic gonadotropin and related glycoprotein hormones in lung cancer cell lines 1991 ·Cancer Letters ·Gerold Bepler, Gabriele Jaques, Herbert K. Oie, Adi F. Gazdar	20
20	Presse-Information 1986 ·LaboratoriumsMedizin ·Gerold Bepler	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact